期刊
LUNG CANCER
卷 87, 期 2, 页码 201-203出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.lungcan.2014.11.014
关键词
Non-small cell lung cancer; KRAS mutation; Sorafenib; RAF inhibitor; Paradoxal activation; Tumor flare
Here we describe a case of striking tumor flare after start of treatment with sorafenib and metformin as part of a phase II clinical trial. Previous reports have described a paradoxal activation of the MAPK pathway after treatment with a weak RAF inhibitor. This mechanism is based on inhibition of a negative feedback loop to upstream effectors of RAF and subsequently increased stimulation of the RAS-RAF-MEK-ERK (MAPK) pathway. We suggest that sorafenib may contribute to tumor progression through this mechanism and clinicians should be aware of this phenomenon when treating NSCLC patients with sorafenib. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据